4 results
Primary: To provide metastatic colorectal cancer patients with access to aflibercept and todocument the overall safety in these patientsSecondary: To document the Health-Related Quality of Life of aflibercept in this patientpopulation
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…
The primary objective of the study is to determine the efficacy of AP26113, as evidenced by objective response rate, in patients with ALK positive locally advanced or metastatic NSCLC whose disease has progressed on therapy with crizotinib.
To investigate the effect the effect of a 3-months treatment with Reslizumab on small airways function in patients with severe eosinophilic asthma, and to relate the changes in small airway function to changes in asthma symptoms and quality of life.